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Abstract
Background: Malignant fibrous histiocytoma (MFH) is a common sarcoma affecting soft tissues of the body,
especially of the extremities or trunk. Prognosis of the abdominal MFH is usually poor.
Case presentation: A 52-year-old female presented to our surgical outpatient clinic with a lower abdominal tumor
that had been gradually increasing in size. Clinical examination revealed a firm, irregularly surfaced, fixed, painless,
child-head-sized tumor located in her lower abdomen. Computed tomography (CT) and magnetic resonance
imaging (MRI) of the abdomen revealed a polycystic tumor at the lower abdomen which was 15 × 13 × 11 cm in
diameter and encased the colorectum to the left back side. A barium enema and a colonoscopy showed direct
invasion to the rectum. In 2001, the tumor had been excised along with a low anterior resection of the rectum
because of direct invasion. The origin of this tumor was the mesorectum. The weight of the excised tumor was
1,500 g, including 800 ml of a brown fluid. A histopathological diagnosis revealed a common type of MFH, in
which mitotic figures are frequently seen.
Conclusion: This patient has survived without recurrence, for approximately 8 years since the completed tumor
resection. It is important to obtain a complete resection during the MFH treatment.
Background
Malignant fibrous histiocytoma (MFH) is a common
sarcoma affecting soft tissues of the body, especially of
the extremities or trunk [1-3]. The tumor cells are
derived from histiocytes capable of fibroblastic transfor-
mation [4]. MFH is an aggressive tumor with a high
potential of demonstrating metastasis to other parts of
the body. The prognosis of patients with abdominal
MFH is usually poor [5].
Primary mesenteric MFH is a rare disease and few
cases have been reported in the English literature [6-10].
We herein report a surgical case of MFH that originated
from the mesorectum and affected the rectum.
Case Report
A 52-year-old female presented to our surgical outpati-
ent clinic with a lower abdominal tumor that had been
gradually increasing in size. She first noticed a fist sized,
painless tumor about four months ago. Clinical exami-
nation revealed a firm, irregularly surfaced, fixed,
painless, child-head-sized tumor in her lower abdomen.
Laboratory data showed that she had a white blood cell
count of 5500/mm
3, hemoglobin of 8.3 g/dl, hematocrit
of 25.4%, platelets count of 429,000/mm
3,n o r m a le l e c -
trolytes, as well as normal blood urea nitrogen levels
and the liver function.
Computed tomography (CT) of the abdomen demon-
strated a large tumor in the lower abdomen which was
15 × 13 × 11 cm in diameter and encased the colorec-
tum to the left back side (Figure 1A). Magnetic reso-
nance imaging (MRI) of the lower abdomen indicated a
polycystic tumor (Figure 1B). A barium enema revealed
that the tumor had encased the rectum toward left pos-
terior, and some parts of the upper rectum had irregular
mucosa (Figure 2A). A colonoscopy revealed an encase-
ment of the upper rectum and also round ulcers with a
white coating, whose histological examination deter-
mined granulation tissue (Figure 2B).
In 2001, this tumor was excised along with a low ante-
rior resection of the rectum for the complete resection
(Figure 3A, B). The mesorectum including the tumor
was well circumscribed from surrounding organs, with
the exception of the rectum. Therefore, the origin of
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uterus and the ovaries had no local lesions. The weight
of the excised tumor was 1,500 g. This tumor included
800 ml of a brown fluid, whose cytological examination
determined class I. A histopathological examination
revealed proliferation of pleomorphic cells in a storiform
pattern (Figure 4A). Mitotic figures were also frequently
observed. Immunohistochemical analyses indicated that
many of the tumor cells were positive for vimentin
(Figure 4B), while tumor cells were negative for cytoker-
atins, desmin, S-100 protein, actins, c-kit, and CD34.
These features are compatible with MFH of a common
type.
The postoperative course was uneventful, and she left
the hospital on the 15th postoperative day. A postopera-
tive follow-up CT revealed no recurrence of the MFH in
any organs since the resection was completed.
Discussion
Retroperioneal and mesenteric MFH have been reported
to occur in the rate from 5.7% to 16% of the total
MFHs cases [1,2,5,11]. Several reports have so far indi-
c a t e dt h a tM F Hd e r i v e df r o mt h er e t r o p e r i t o n e u m
includes mesenteric MFH because it is difficult to deter-
m i n et h et r u eo r i g i no ft h eh u g et u m o r .D u et ot h i s
condition, mesenteric MFH is very rarely observed
A
B
Figure 1 A) An abdominal CT revealed a large uneven tumor in the lower abdomen and encased the colorectum to the left back side
(arrows). B) An MRI of the lower abdomen revealed a polycystic tumor with a part of the thickened wall (arrows).
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mesorectum because the huge tumor was limited to
within the capsule of the mesorectum.
MFH is an aggressive tumor with a high potential of
metastasis to other parts of the body. The rates of local
recurrence and distant metastasis are 44% and 42%,
respectively [1]. The most frequent metastatic site is the
lung (82%), followed by the lymph nodes (32%) [1].
Although the 5-year survival rate of all MFH patients that
underwent surgery is 67.2% [11], the 5-year survival rate
of patients with abdominal MFH is reportedly 14% [5]. On
the other hand, the 5-year survival rate of patients with
mesenteric MFH has not been reported because the dis-
ease is extremely rare. The current treatment of choice for
A B B
Figure 2 A) A barium enema revealed an encasement of the sigmoid colon and rectum toward the left back side. Some parts of the
upper rectum had irregular mucosa (arrows). B) A colonoscopy revealed a round ulcer with a white coating (arrows).
B A
Figure 3 A) A laparotomy revealed a child-head-sized tumor that encased the other organs (arrows). B) An operative specimen revealed
a polycystic tumor with a part of the thickened wall.
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sion of the tumor with an aim for a tumor-free margin.
Presently, the efficacy of adjuvant chemotherapy or radia-
tion has not been clear in the case of retroperitoneal and
visceral MFH. Therefore, this patient received neither
adjuvant chemotherapy nor radiation.
Mesenteric MFH initially grows without any signifi-
cant clinical symptoms, and finally produces clinical
symptoms and signs later when it compresses or invades
the adjacent organs [9]. In this case, she noticed the
lower abdominal tumor without any symptoms: never-
theless, the tumor size was 15 × 13 × 11 cm and the
tumor had directly invaded to the rectum. Therefore, a
complete tumor resection combined with a low anterior
resection of the rectum was needed. A previous report
indicated that colonic lesions of retroperitoneal MFH
were detected by a barium enema and colonoscopic
examination before the laparotomy [12]. In the present
case, rectal ulcers were also identified by a barium
enema and colonoscopic examination before the laparot-
omy. Moreover, a histologic examination of the resected
specimen clearly demonstrated a submucosal invasion
by the MFH. It is very important that the requirement
of the combined resection with other organs is decided
before the operation begins.
The efficacy of chemotherapy against advanced or
metastatic MFH is still unclear. On the other hand, sev-
eral phase studies which investigate the efficacy of che-
motherapy against advanced or metastatic soft tissue
sarcoma including MFH, have been reported [13-16].
These studies indicated that doxorubicin and ifosfamide
are the most active agents for the treatment of this clini-
c a lc o n d i t i o n[ 1 3 - 1 6 ] .H o w e v e r ,t h er e s p o n s er a t eo f
these agents has been reported to range between 10%
and 36%, and the median overall survival of these agents
has been described to be between 10 and 12 months
[13-16]. Therefore, in order to obtain an improvement
in the survival in the patients with soft tissue sarcoma
including MFH, further investigation of the new avail-
able agents is thus called for.
Conclusion
This patient has survived without recurrence for
approximately 8 years after the completed tumor resec-
tion. A complete resection is important to obtain a
favorable prognosis for MFH.
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